Tag: Psoriasis
Biologic Tx for Psoriasis May Reduce Coronary Inflammation
Findings indicated by perivascular fat attenuation index, as measured by coronary CT angiography
Psoriasis Patients Often Use CAMs When Traditional Meds Fail
41, 39.5 percent use alternative, complementary therapies; higher use seen with severe psoriasis
Abdominal Obesity May Raise Risk for Psoriasis
High waist circumference, regardless of overall body mass index, tied to higher risk
Carotid Atherosclerosis Predicts CV Events in Psoriatic Disease
After controlling for Framingham Risk Score, TPA, mean and max cIMT predict incident CVEs
Infection Risk Lower With Certain Psoriasis Treatments
Risk for serious infection reduced for new users of apremilast, etanercept, ustekinumab versus methotrexate
Higher Risk for Mental Disorders Seen in Patients With Psoriasis
Time to onset found to be two to three months for anxiety disorders and other conditions
Psoriasis Symptoms, Quality of Life Tied to Disease Severity
Findings show alignment of patient-reported symptoms, clinician assessment tools
DLQI With ‘Not Relevant’ Answers May Underrate Psoriasis Severity
Objective, subjective disease severity worse for those responding 'not relevant' versus 'not at all'
Drug Survival Rates Highest for Ustekinumab for Pediatric Psoriasis
Drug survival rates higher than for adalimumab, etanercept for all treatment and psoriasis types
Age, Race Impact Atherosclerotic Risk With Psoriasis
Increased risk for atherosclerotic CVD seen at younger age in African-Americans with psoriasis
